Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PAXIL vs BRISDELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin (5-HT) from the synaptic cleft, leading to increased serotonin levels.
Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder (off-label),Vasomotor symptoms of menopause (off-label)
FDA-approved: Treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause.,Off-label: Management of depression, anxiety disorders, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder.
20 mg orally once daily, typically in the morning; may be increased in 10 mg/day increments at intervals of at least 1 week to a maximum of 50 mg/day.
8 mg orally once daily, taken at bedtime.
Mean terminal half-life 21 hours (range 3–65 hours); steady-state achieved within 7–14 days; nonlinear kinetics with dose increase leading to disproportionate increases in half-life due to saturable hepatic metabolism (CYP2D6).
Terminal elimination half-life is approximately 9-11 hours for paroxetine (the active ingredient in Brisdelle). This supports once-daily dosing; steady-state is achieved within 7-14 days.
Extensively metabolized primarily via cytochrome P450 (CYP) 2D6, with minor contributions from CYP3A4 and CYP1A2. The parent drug accounts for <1% of excretion. Metabolites include paroxetine catechol and paroxetine glucuronide conjugates.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6. Metabolites are glucuronidated and excreted renally.
Renal: 64% (2% unchanged, 62% as metabolites); Fecal: 36% via bile; urinary excretion of unchanged paroxetine <2%.
Primarily renal excretion as metabolites; approximately 60% of a radiolabeled dose is recovered in urine and 30% in feces over 10 days. Less than 1% excreted unchanged.
93–95% bound to plasma proteins (primarily alpha-1-acid glycoprotein and albumin).
Approximately 95% bound to plasma proteins, primarily to albumin and alpha-1 acid glycoprotein.
11 L/kg (range 3–28 L/kg); extensive tissue distribution with concentrations in CNS exceeding plasma.
Volume of distribution is about 3-28 L/kg (mean ~13 L/kg), indicating extensive tissue distribution.
Oral: 50% (range 30–60%; limited by first-pass metabolism); food does not significantly affect extent of absorption, but may slightly delay Tmax.
Oral bioavailability is approximately 50-100% due to extensive first-pass metabolism; absolute bioavailability is about 50% for the immediate-release formulation.
For GFR <30 m L/min: initial dose 10 mg/day; maximum 40 mg/day. Hemodialysis: no supplemental dose needed.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥ 30 m L/min). For severe renal impairment (Cr Cl < 30 m L/min) or end-stage renal disease, not recommended due to lack of data.
Child-Pugh Class A or B: initial dose 10 mg/day; maximum 40 mg/day. Child-Pugh Class C: not recommended.
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate hepatic impairment (Child-Pugh B): maximum dose 4 mg orally once daily. Severe hepatic impairment (Child-Pugh C): contraindicated.
Not approved for patients <18 years; off-label use for OCD in children 7–17 years: starting 10 mg/day, titrate by 10 mg/week to target 20–50 mg/day (max 60 mg/day).
Not approved for use in pediatric patients; safety and efficacy not established.
Initial dose 10 mg/day; maximum 40 mg/day. Increase in 10 mg increments at intervals of at least 1 week.
For patients >65 years, start with 4 mg orally once daily at bedtime; may increase to 8 mg once daily based on response and tolerability. Monitor closely for sedation and falls.
Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Paroxetine is not approved for use in pediatric patients.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality risk in children, adolescents, and young adults,Serotonin syndrome (potentially life-threatening) when co-administered with other serotonergic drugs,MAOI interaction (at least 14-day washout period),Discontinuation syndrome (dizziness, sensory disturbances, anxiety, etc.) upon abrupt withdrawal,Increased risk of bleeding (especially with NSAIDs, aspirin, or anticoagulants),Activation of mania/hypomania in patients with bipolar disorder,Seizure risk (use caution in patients with seizure disorders),Angle-closure glaucoma (pupillary dilation risk),Hyponatremia (elderly, volume-depleted patients),Bone fracture risk (epidemiological studies),Fetal harm (epidemiological data suggest increased risk of cardiovascular malformations, particularly ventricular outflow obstructions, with first-trimester exposure; consider risk/benefit)
Suicidality risk in young adults,Serotonin syndrome with concurrent serotonergic drugs,Bone fractures risk,Sexual dysfunction,Abnormal bleeding risk,Angle-closure glaucoma risk,Hyponatremia in elderly or volume-depleted patients,Discontinuation syndrome upon abrupt withdrawal,Pregnancy: Potential harm to neonates (persistent pulmonary hypertension, serotonin syndrome),Lactation: Excreted in breast milk
Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Concurrent use of pimozide or thioridazine (QT prolongation and pharmacokinetic interaction),Hypersensitivity to paroxetine or any component of the formulation
Concomitant use with MAOIs (or within 14 days of MAOI discontinuation),Concomitant use with thioridazine,Concomitant use with pimozide,Hypersensitivity to paroxetine or any component,Pregnancy (especially third trimester) due to risk of neonatal complications
No significant food interactions; may be taken with or without food. Grapefruit juice does not interact. Avoid excessive alcohol.
Avoid alcohol due to additive central nervous system depression. No specific food interactions; take without regard to meals.
First trimester: Risk of congenital cardiac defects (primarily ventricular and atrial septal defects) with relative risk ~1.5-1.7; persistent pulmonary hypertension of the newborn (PPHN) risk increased ~2-fold; overall absolute risk <.5% for major malformations. Second/third trimester: Risk of preterm delivery, low birth weight, neonatal serotonin discontinuation syndrome (irritability, feeding difficulties, respiratory distress, tremors).
Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses greater than human therapeutic doses. In humans, retrospective studies suggest a small increased risk of congenital heart defects (primarily ventricular septal defects) with first-trimester exposure. Third-trimester exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and neonatal withdrawal syndrome (respiratory distress, feeding difficulties, jitteriness).
Paroxetine is excreted into breast milk with an estimated infant dose of ~1% of maternal weight-adjusted dose; M/P ratio is approximately 0.56. Cases of irritability, poor feeding, and drowsiness in breastfed infants have been reported; cautious use recommended, with monitoring for adverse effects.
Paroxetine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.7. Estimated infant dose is 1-2% of maternal weight-adjusted dose. No adverse effects have been consistently reported in breastfed infants, but caution is advised due to potential for serotonin-related effects. Benefits versus risks should be assessed.
Increased plasma volume and hepatic metabolism in pregnancy may reduce paroxetine levels; consider upward dose titration (20-40% increase) in second and third trimesters based on clinical response; monitor for worsening depression; taper gradually postpartum to avoid discontinuation syndrome.
No specific dose adjustment is recommended solely due to pregnancy; however, pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may lead to decreased drug levels. Clinical monitoring and dose titration based on therapeutic response and tolerability are advised. Avoid abrupt discontinuation to prevent withdrawal effects.
Paroxetine has a short half-life and is associated with significant withdrawal syndrome upon abrupt discontinuation; taper slowly. It is the most anticholinergic SSRI, causing more constipation, dry mouth, and sedation. Use with caution in elderly due to hyponatremia risk. It is also a weak inhibitor of CYP2D6, potentially increasing levels of co-administered drugs like tamoxifen or metoprolol.
BRISDELLE (paroxetine mesylate) is a selective serotonin reuptake inhibitor (SSRI) indicated for vasomotor symptoms (VMS) in menopause. It is the only non-hormonal therapy FDA-approved for moderate to severe VMS. Dosing starts at 7.5 mg once daily, typically at bedtime to minimize daytime sedation. Avoid concurrent use with MAOIs, other SSRIs/SNRIs, or strong CYP2D6 inhibitors (e.g., paroxetine itself). Monitor for serotonin syndrome, especially with triptans or linezolid. Discontinue gradually to avoid withdrawal symptoms. Note that paroxetine is pregnancy category D; use effective contraception.
Take exactly as prescribed; do not stop suddenly or change dose without consulting doctor.,May cause drowsiness; avoid driving until you know how you react.,Avoid alcohol while taking this medication.,Notify doctor if you experience serotonin syndrome symptoms: agitation, hallucinations, fast heartbeat, fever, muscle stiffness, nausea, diarrhea.,Inform all healthcare providers you are taking paroxetine, especially before surgery or any new medication.,Do not take with MAOIs or within 14 days of stopping MAOIs.
Take BRISDELLE at bedtime to reduce daytime drowsiness.,Do not crush or chew the capsule; swallow whole.,It may take 2–4 weeks to see full benefit for hot flashes.,Avoid alcohol as it can increase sedation.,Do not stop suddenly; taper under medical guidance.,Report any suicidal thoughts, worsening depression, or unusual behavior changes.,Contact doctor if you experience severe headache, nausea, or rapid heartbeat (serotonin syndrome).,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PAXIL vs BRISDELLE, answered by our medical review team.
PAXIL is a SSRI Antidepressant that works by Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin (5-HT) from the synaptic cleft, leading to increased serotonin levels.. BRISDELLE is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PAXIL and BRISDELLE depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PAXIL is: 20 mg orally once daily, typically in the morning; may be increased in 10 mg/day increments at intervals of at least 1 week to a maximum of 50 mg/day.. The standard adult dose of BRISDELLE is: 8 mg orally once daily, taken at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PAXIL and BRISDELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PAXIL is classified as Category C. First trimester: Risk of congenital cardiac defects (primarily ventricular and atrial septal defects) with relative risk ~1.5-1.7; persistent pulmonary hypertension of the newborn . BRISDELLE is classified as Category C. Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses grea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.